http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lu-Lu Zhang,Yi-Yang Li,Jiang Hu,Guan-Qun Zhou,Lei Chen,Wen-Fei Li,Ai-Hua Lin,Jun Ma,Zhen-Yu Qi,Ying Sun 대한암학회 2018 Cancer Research and Treatment Vol.50 No.4
Purpose Local relapse-free survival (LRFS) differs widely among patients with T4 category nasopharyngeal carcinoma (NPC). We aimed to build a nomogram incorporating clinicopathological information to predict LRFS in T4 NPC after definitive intensity-modulated radiation therapy (IMRT). Materials and Methods Retrospective study of 415 Chinese patients with non-metastatic T4 NPC treated with definitive IMRT with or without chemotherapy at our cancer center between October 2009 and September 2013. The nomogram for LRFS at 3 and 5 years was generated based on multivariate Cox proportional hazards regression, and validated using bootstrap resampling, assessing discriminative performance using the concordance index (C-index) and determining calibration ability via calibration curves. Results Five-year LRFS was 88.8%. We identified and incorporated four independent prognostic factors for LRFS: ethmoid sinus invasion, primary gross tumor volume, age, and pretreatment body mass index. The C-index of the nomogram for local recurrence was 0.732 (95% confidence interval, 0.726 to 0.738), indicating excellent predictive accuracy. The calibration curve revealed excellent agreement between nomogram-predicted and observed LRFS probabilities. Risk subgroups based on total point score cutoff values enabled effective discrimination of LRFS. Conclusion This pretreatment nomogram enables clinicians to accurately predict LRFS in T4 NPC after definitive IMRT, and could help to facilitate personalized patient counselling and treatment strategies.
Wang Lu,Dai Ying-Jie,Cui Yu,Zhang Hong,Jiang Chang-Hao,Duan Ying-Jie,Zhao Yong,Feng Ye-Fang,Geng Shi-Mei,Zhang Zai-Hui,Lu Jiang,Zhang Ping,Zhao Li-Wei,Zhao Hang,Ma Yu-Tong,Song Cheng-Guang,Zhang Yi,Ch 대한뇌졸중학회 2023 Journal of stroke Vol.25 No.3
Background and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset. Methods In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Results Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; <i>P</i>=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, <i>P</i>=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group. Conclusion This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.
Current Status of Etiology, Epidemiology, Clinical Manifestations and Imagings for COVID-19
Jiang Meng Di,Zu Zi Yue,Schoepf U. Joseph,Savage Rock H.,Zhang Xiao Lei,Lu Guang Ming,Zhang Long Jiang 대한영상의학회 2020 Korean Journal of Radiology Vol.21 No.10
Coronavirus disease 2019 (COVID-19) is a transmissible respiratory disease that was initially reported in Wuhan, China in December 2019. With the alarming levels of COVID-19 spread worldwide, the World Health Organization characterized COVID-19 as a pandemic. Over the past several months, chest CT has played a vital role in early identification, disease severity assessment, and dynamic disease course monitoring of COVID-19. The published data has enriched our knowledge on the etiology, epidemiology, clinical manifestations, and pathologic findings of COVID-19. Additionally, as the imaging spectrum of the disease continues to be defined, extrapulmonary infections or other complications will require further attention. This review aims to provide an updated framework and essential knowledge with which radiologists can better understand COVID-19.
Identification and characterization of presence/absence variation in maize genotype Mo17
Lu Jiang,Yuanda Lv,Tan Li,Han Zhao,Tifu Zhang 한국유전학회 2015 Genes & Genomics Vol.37 No.6
Presence/absence variation (PAV), a major class of genome structure variation, is pervasive in the maize genome. PAVs present in the B73 but absent from the Mo17 genome have been reported in previous studies. Here, the next-generation sequencing was used to identify the PAVs present in Mo17 but absent from B73. A total of 119 PAVs were identified, of which 57 were validated by PCR. Using the intermated B73 9 Mo17 segregating population, 57 validated PAVs were mapped into the genetic map. These PAVs were dispersed on the ten chromosomes. Also, several large genetic regions of PAVs were identified. This suggested the possibility that large genetic fragments in Mo17 were absent from the B73 genome. Several PAVs were also found to be related to disease resistance suggesting that presence/absence variations in the genome may play a role in disease resistances in maize. In addition, the majority of the genes within PAV were transcriptionally silenced or expressed at low levels in some tissues, especially for PAVs related to disease resistance. The results of this study not only provided the identities of additional PAVs in maize but also helped understand the functional role of PAVs in this agriculturally important crop.
Research on a New 12-Pulse Step-Up and Step-Down Aviation Auto-Transformer Rectifier
Jiang, Fan,Ge, Hong-juan,Dong, Xiao-xu,Zhang, Lu The Korean Institute of Power Electronics 2018 JOURNAL OF POWER ELECTRONICS Vol.18 No.1
This paper presents a new step-up and step-down multi-pulse auto-transformer rectifier unit (ATRU) topology. This structure can achieve a wide range of output voltages, which solves the problem of auto-transformer output voltage being difficult to regulate. Adding middle taps to the primary winding and reasonably setting the number of auto-transformer windings, constituted two groups of three-phase output voltages with a $30^{\circ}$ phase difference. Multi-pulse output DC voltage is obtained after a three-phase output voltage across two rectifier bridges and inter-phase reactor. Thus, the output DC voltage is related to the number and configuration of the auto-transformer winding. In this paper, the relationship between the voltage ratio of the auto-transformer and the ratio of winding, input current and auto-transformer kilovoltampere rating are deduced and validated by simulations. On this basis, the output voltage range is optimized. An experiment on two different voltage ratio principle prototypes was carried out to verify the correctness of the analysis design.
Lu Xiao,Xu Guangyu,Lin Zhidi,Zou Fei,Liu Siyang,Zhang Yuxuan,Fu Wei,Jiang Jianyuan,Ma Xiaosheng,Song Jian 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Spinal cord injury (SCI) brings a heavy burden to individuals and society, and there is no effective treatment at present. Exosomes (EX) are cell secreted vesicles containing molecules such as nucleic acids and proteins, which hold promise for the treatment of SCI. Netrin-1 is an axon guidance factor that regulates neuronal growth. We investigated the effects of engineered EX enriched in netrin-1 chemically synthetic modified message RNA (modRNA) in treating SCI in an attempt to find a novel therapeutic approach for SCI.Netrin-1 modRNA was transfected into bone marrow mesenchymal stem cells to obtain EX enriched with netrin-1 (EX-netrin1). We built an inflammatory model in vitro with lipopolysaccharide (LPS) in vitro to study the therapeutic effect of EX-netrin1 on SCI. For experiments in vitro, ELISA, CCK-8 assay, immunofluorescence staining, lactate dehydrogenase release experiments test, real-time quantitative polymerase chain reaction, and western blot were conducted. At the same time, we constructed a rat model of SCI. MRI, hematoxylin-eosin and Nissl staining were used to assess the extent of SCI in rats.In vitro experiments showed that EX had no effect on the viability of oligodendrocytes and PC12 cells. EX-netrin1 could attenuate LPS-induced inflammation and pyroptosis and accelerate axonal/dentritic growth in PC12 cells/oligodendrocytes. In addition, netrin-1 could activate the PI3K/AKT/mTOR signalling pathway upon binding to its receptor unc5b. When Unc5b and PI3K were inhibited, the effect of EX-netrin1 was weakened, which could be reversed by PI3K or mTOR activator. Our in vivo experiments indicated that EX-netrin1 could promote recovery in rats with SCI.We found that EX-netrin1 regulated inflammation, pyroptosis and axon growth in SCI via the Unc5b/PI3K/AKT/mTOR pathway, which provides a new strategy for the treatment of SCI.